Innovation of the Year

Browse this Section...
Home >> Events >> 2014 Innovation Celebration >> Innovation of the Year

Tuberculosis Anti-Virulence Chemical Compounds

Dr. Robert Abramovitch

Associate Professor of Microbiology and Molecular Genetics

Tuberculosis (TB) represents one of the single most lethal infectious agents worldwide, second only in lethality to HIV/AIDS according to the World Health Organization. This technology is a pair of biosensors that enable the identification of compounds that inhibit M. tuberculosis virulence adaptation physiologies required for chronic infections. One reason that TB has proven difficult to eradicate, particularly in poorer countries, is that current therapies require a six month long course of drugs to cure the disease. This has resulted in continued spread of the disease and the emergence of multidrug resistant TB. The compounds may work to cut TB treatment time considerably from the current average of 6 months.

MSU Technologies is pleased to recognize Dr. Abramovitch and his team for their research and innovations.